The revenue guidance cut is the dominant signal here — the profit beat is largely cost-driven and not sustainable if top-line momentum continues to decelerate. Watch Q3 trading report on Nov 6 for confirmation of the H2 step-up in Orthopaedics and Bioactives; if US Knee Implants don't inflect, further downside is likely.
Price Chart
Executive Summary
Smith & Nephew reported H1 2026 revenue of $3,097M (+2.3% underlying, +4.6% reported) and Q2 revenue of $1,597M (+1.6% underlying). While trading profit grew 8.1% to $566M and EPSA rose 11.0% to 47.7 cents, the company cut full-year revenue guidance from ~6% to ~4% due to weakness in US Orthopaedics and Advanced Wound Bioactives. The miss on top-line guidance and ongoing structural headwinds in Knee Implants and skin substitutes outweigh the profit beat and $500M buyback, making this a bearish read-through for the stock.
Key Facts
- Q2 underlying revenue growth of 1.6% missed expectations; full-year revenue guidance cut from ~6% to ~4%
- H1 trading profit up 8.1% to $566M, driven by $130M in efficiency savings and tariff refunds
- US Knee Implants declined -7.2% in Q2; US Hip Implants declined -1.5% after four quarters of above-market growth
- Advanced Wound Bioactives revenue fell -12.7% underlying in Q2 due to skin substitute reimbursement changes
- Sports Medicine & ENT remained strong with Q2 underlying growth of 8.6%
- EPSA up 11.0% to 47.7 cents; basic EPS up 6.2% to 35.6 cents
- Free cash flow was $231M, down 5.2% YoY due to $51M increase in capex
- Net debt/EBITDA leverage at 1.8x; $500M buyback announced in May with $216M settled as of Aug 3
- Interim dividend increased 4.0% to 15.6 cents per share
- FDA granted De Novo classification for TESSA Spatial Surgery System
Financial Impact
Full-year revenue guidance cut from ~6% to ~4% growth; trading profit guidance unchanged at ~$1.3B; free cash flow guidance unchanged at ~$800M
Risk Factors
- US Orthopaedics recovery may be slower than guided, especially Knee Implants ahead of LANDMARK launch
- Skin substitute headwind could exceed the upper end of the $20-40M guided range
- Tariff refunds may not repeat in H2, exposing the P&L to the original tariff headwind
- China VBP implementation in H2 2026 could pressure Sports Medicine and ENT growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-089991 |
| Document: 0001104659-26-089991-index-headers.html | 0001104659-26-089991 |
| Document: 0001104659-26-089991-index.html | 0001104659-26-089991 |
| Document: 0001104659-26-089991.txt | 0001104659-26-089991 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 6-K | $27.80 $26.82 | ▼ −3.53% | ▼ −6.09% | $26.42 (−4.96%) |
Sep 16, 2026 16d ago | 6-K | $27.80 $26.82 | ▼ −3.53% | ▼ −6.09% | $26.42 (−4.96%) |
Sep 11, 2026 21d ago | 6-K | $27.50 $27.56 | ▲ +0.22% | ▲ +0.44% | $26.42 (−3.93%) |
Sep 10, 2026 22d ago | 6-K | $27.62 $27.78 | ▲ +0.58% | ▲ +1.08% | $26.42 (−4.34%) |
Sep 10, 2026 22d ago | 6-K | $27.62 $27.78 | ▲ +0.58% | ▲ +1.08% | $26.42 (−4.34%) |
Sep 9, 2026 23d ago | 6-K | $27.80 $28.06 | ▲ +0.94% | ▲ +1.27% | $26.42 (−4.96%) |
Sep 8, 2026 24d ago | 424B5 | $27.87 $28.01 | ▲ +0.50% | ▲ +1.62% | $26.42 (−5.20%) |
Sep 2, 2026 4w ago | 6-K | $28.66 $27.62 | ▼ −3.63% | ▼ −2.67% | $26.42 (−7.82%) |
Sep 2, 2026 4w ago | 6-K | $28.66 $27.62 | ▼ −3.63% | ▼ −2.67% | $26.42 (−7.82%) |
Sep 1, 2026 4w ago | 6-K | $28.97 $27.80 | ▼ −4.04% | ▼ −4.12% | $26.42 (−8.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access